PY2052230A - Compuestos inhibidores de rip1 y métodos para fabricar y utilizar los mismos - Google Patents

Compuestos inhibidores de rip1 y métodos para fabricar y utilizar los mismos

Info

Publication number
PY2052230A
PY2052230A PY202002052230A PY2052230A PY2052230A PY 2052230 A PY2052230 A PY 2052230A PY 202002052230 A PY202002052230 A PY 202002052230A PY 2052230 A PY2052230 A PY 2052230A PY 2052230 A PY2052230 A PY 2052230A
Authority
PY
Paraguay
Prior art keywords
rip1
manufacturing
methods
inhibiting compounds
compounds
Prior art date
Application number
PY202002052230A
Other languages
English (en)
Inventor
Darwish Ihab
Yu Jiaxin
Shaw Simon
Bhamidipati Somasekhar
Taylor Vanessa
Chen Yan
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of PY2052230A publication Critical patent/PY2052230A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describen compuestos inhibidores de quinasas, tales como compuestos inhibidores de quinasa de proteína 1 que interactúa con el recpetor (RIP1), así como composiciones farmacéuticas y combinaciones que comprenden dichos compuestos inhibidores. Los compuestos, composiciones farmacéuticas y/o combinaciones descritos pueden usarse para tratar o prevenir una enfermedad o afección asociada a quinasas, particularmente una enfermedad o afecciòn asociada a RIP1.
PY202002052230A 2019-09-06 2020-09-07 Compuestos inhibidores de rip1 y métodos para fabricar y utilizar los mismos PY2052230A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962897223P 2019-09-06 2019-09-06
US201962932404P 2019-11-07 2019-11-07
US202063001016P 2020-03-27 2020-03-27
US202063004290P 2020-04-02 2020-04-02
US202063004319P 2020-04-02 2020-04-02

Publications (1)

Publication Number Publication Date
PY2052230A true PY2052230A (es) 2021-10-05

Family

ID=72613994

Family Applications (2)

Application Number Title Priority Date Filing Date
PY202002052258A PY2052258A (es) 2019-09-06 2020-09-07 Compuestos inhibidores de rip1 y métodos para fabricar y utilizar el mismo
PY202002052230A PY2052230A (es) 2019-09-06 2020-09-07 Compuestos inhibidores de rip1 y métodos para fabricar y utilizar los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PY202002052258A PY2052258A (es) 2019-09-06 2020-09-07 Compuestos inhibidores de rip1 y métodos para fabricar y utilizar el mismo

Country Status (21)

Country Link
US (1) US11564930B2 (es)
EP (1) EP4025575B1 (es)
JP (2) JP7493586B2 (es)
KR (1) KR102793185B1 (es)
CN (1) CN114728958B (es)
AU (1) AU2020341708B2 (es)
BR (1) BR112022002378A2 (es)
CA (1) CA3149729A1 (es)
CO (1) CO2022002374A2 (es)
CR (1) CR20220075A (es)
DO (1) DOP2022000042A (es)
EC (1) ECSP22016567A (es)
IL (1) IL290781A (es)
JO (1) JOP20220056A1 (es)
MX (1) MX2022002717A (es)
MY (1) MY198690A (es)
PE (1) PE20221762A1 (es)
PH (1) PH12022550537A1 (es)
PY (2) PY2052258A (es)
TW (1) TW202122397A (es)
WO (1) WO2021046437A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL278416B2 (en) 2018-05-03 2023-12-01 Rigel Pharmaceuticals Inc RIP1 inhibitory compounds and methods for their preparation and use
MX2022002717A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
PE20221628A1 (es) 2019-09-06 2022-10-19 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
HRP20251589T1 (hr) * 2019-11-07 2026-01-30 Rigel Pharmaceuticals, Inc. Heterociklični spojevi koji inhibiraju rip1
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
AR122703A1 (es) 2020-07-01 2022-09-28 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
WO2022237890A1 (zh) * 2021-05-14 2022-11-17 中国医药研究开发中心有限公司 氮杂卓类稠环化合物及其医药用途
WO2022258052A1 (zh) * 2021-06-11 2022-12-15 劲方医药科技(上海)有限公司 杂环内酰胺类化合物，其制法与医药上的用途
WO2023138317A1 (zh) * 2022-01-21 2023-07-27 中国科学院上海药物研究所 具有ripk1抑制活性的化合物、其制备方法及其用途
AU2023224057A1 (en) * 2022-02-28 2024-08-15 Sironax Ltd. Rip1 modulators, preparations, and uses thereof
CN115201250B (zh) * 2022-09-14 2022-11-25 中铁三局集团第三工程有限公司 一种冷再生沥青混合料热可逆老化程度的量化方法
AU2024309577A1 (en) 2023-06-26 2026-01-15 Eli Lilly And Company Dosage regimens for the treatment of autoimmune and inflammatory diseases using ly3871801
WO2025153090A1 (zh) * 2024-01-19 2025-07-24 无锡奕拓医药科技有限责任公司 一种多并环化合物、其药物组合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 多重層型バリアー構造体
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
CA2696349A1 (en) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
AU2015304851A1 (en) 2014-08-21 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as RIP1 kinase inhibitors as medicaments
RU2017131862A (ru) 2015-02-13 2019-03-13 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед КРИСТАЛЛИЧЕСКИЕ ФОРМЫ (S)-5-БЕНЗИЛ-N-(5-МЕТИЛ-4-ОКСО-2,3,4,5-ТЕТРАГИДРОБЕНЗО[b][1,4]ОКСАЗЕПИН-3-ИЛ)-4H-1,2,4-ТРИАЗОЛ-3-КАРБОКСАМИДА
CA3094197C (en) 2015-07-02 2023-02-28 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
DK3362449T3 (da) 2015-10-13 2021-07-19 Inst Nat Sante Rech Med Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
CN108431004B (zh) * 2015-10-23 2021-02-12 武田药品工业株式会社 杂环化合物
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN111655678B (zh) 2018-01-05 2023-08-22 广州市恒诺康医药科技有限公司 细胞凋亡信号调节激酶-1抑制剂及其应用
PE20211383A1 (es) 2018-05-03 2021-07-27 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
IL278416B2 (en) 2018-05-03 2023-12-01 Rigel Pharmaceuticals Inc RIP1 inhibitory compounds and methods for their preparation and use
TW202019913A (zh) 2018-06-26 2020-06-01 中國科學院上海有機化學研究所 細胞壞死抑制劑及其製備方法和用途
CN111138448B (zh) 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2020088194A1 (zh) 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
PE20221628A1 (es) 2019-09-06 2022-10-19 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos
MX2022002717A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Also Published As

Publication number Publication date
PY2052258A (es) 2022-05-10
IL290781A (en) 2022-04-01
WO2021046437A1 (en) 2021-03-11
JP2022546605A (ja) 2022-11-04
MY198690A (en) 2023-09-16
DOP2022000042A (es) 2022-08-15
PH12022550537A1 (en) 2023-03-20
CA3149729A1 (en) 2021-03-11
PE20221762A1 (es) 2022-11-11
CN114728958A (zh) 2022-07-08
ECSP22016567A (es) 2022-08-31
US20210069208A1 (en) 2021-03-11
BR112022002378A2 (pt) 2022-06-14
JP2024050568A (ja) 2024-04-10
JP7493586B2 (ja) 2024-05-31
KR20220042206A (ko) 2022-04-04
KR102793185B1 (ko) 2025-04-09
CN114728958B (zh) 2025-05-02
CO2022002374A2 (es) 2022-08-09
JOP20220056A1 (ar) 2023-01-30
CR20220075A (es) 2022-07-14
AU2020341708A1 (en) 2022-03-17
EP4025575A1 (en) 2022-07-13
EP4025575B1 (en) 2025-12-17
TW202122397A (zh) 2021-06-16
AU2020341708B2 (en) 2024-01-04
US11564930B2 (en) 2023-01-31
MX2022002717A (es) 2022-08-10

Similar Documents

Publication Publication Date Title
PY2052230A (es) Compuestos inhibidores de rip1 y métodos para fabricar y utilizar los mismos
PY2052250A (es) Compuestos inhibidores de rip1 y métodos para fabricar y usar los mismos
DOP2023000169A (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
CL2022002695A1 (es) Inhibidores de rip1k
ECSP20077518A (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
MX2022005509A (es) Compuestos inhibidores de rip1 heterociclicos.
CL2018003267A1 (es) Cápsulas que comprenden bencilpropargiléteres para usar como inhibidores de la nitrificación.
CL2022003812A1 (es) Inhibidores de rip1k
PY2055444A (es) Composiciones nematicidas
AR120412A1 (es) Compuestos heterocíclicos inhibidores de rip1
CO2023012077A2 (es) Inhibidores heterocíclicos de la cinasa rip1